Rubicon Research (NSE:RUBICON) OCF Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:RUBICON Rubicon Research Ltd NSE:RUBICON
18 GF Score
Price ₹1,439.60
! 3 Warning Signs
View Full Analysis

What is Rubicon Research OCF Margin %?

Rubicon Research NSE:RUBICON +1.45% 18 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 962 Drug Manufacturers companies, Rubicon Research ranks worse than 65.9% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Rubicon Research's Cash Flow from Operations for the three months ended in Mar. 2026 was ₹0 Mil. Rubicon Research's Revenue for the three months ended in Mar. 2026 was ₹5,139 Mil. Therefore, Rubicon Research's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Rubicon Research's current OCF Yield % is 0.19%.

The historical rank and industry rank for Rubicon Research's OCF Margin % or its related term are showing as below:

NSE:RUBICON' s OCF Margin % Range Over the Past 10 Years
Min: -19.43   Med: 7.09   Max: 12.39
Current: 3.29

During the past 4 years, the highest OCF Margin % of Rubicon Research was 12.39%. The lowest was -19.43%. And the median was 7.09%.

NSE:RUBICON's OCF Margin % is ranked worse than
65.9% of 962 companies
in the Drug Manufacturers industry
Industry Median: 10.035 vs NSE:RUBICON: 3.29

Rubicon Research OCF Margin % Related Terms

Rubicon Research OCF Margin % Historical Data

* Premium members only.

The historical data trend for Rubicon Research's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rubicon Research OCF Margin % Chart

Rubicon Research Annual Data
Trend Mar23 Mar24 Mar25 Mar26
OCF Margin %
-19.43 2.49 12.39 11.69

Rubicon Research Quarterly Data
Mar23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial 0.00 0.00 12.69 0.00 0.00

NSE:RUBICON vs LLY, JNJ, ABBV: OCF Margin % Comparison

For the Drug Manufacturers - General subindustry, Rubicon Research's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rubicon Research OCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Rubicon Research's OCF Margin % falls into.


NSE:RUBICON
18GF Score
Rubicon Research Ltd NSE:RUBICON
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rubicon Research OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Rubicon Research's OCF Margin for the fiscal year that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=2050.46/17539.56
=11.69 %

Rubicon Research's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=0/5139.15
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Rubicon Research (NSE:RUBICON) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Rubicon Research and its competitors. According to the industry distribution chart, Rubicon Research ranks #634 out of 962 companies in the Drug Manufacturers industry, placing it in the top 65.9%.
Is Rubicon Research's OCF Margin % too high?
Rubicon Research's current OCF Margin % is 0.00%. Based on the distribution chart, Rubicon Research ranks #634 out of 962 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's OCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #634 out of 962 companies for OCF Margin %. This places Rubicon Research in the lower half of its industry. The industry median OCF Margin % is 10.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rubicon Research Business Description

Other Exchanges 544578:India
Address Road No. 33, MedOne House, B-75, Wagle Estate, Thane West, Thane, MH, IND, 400 604
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score

Get the complete analysis for NSE:RUBICON

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,439.60
Price